Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of R-107 for treatment-resistant major depressive disorder
ACTRN12618001048279Phase 2Completed
- Sponsor
- Douglas Pharmaceuticals
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of R107 in major depressive disorder (MDD), sponsored by Douglas Pharmaceuticals. Primary endpoint: Safety and tolerability of extended release R-107. Started Aug 2019; status: completed.
02
Drugs
R107
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12618001048279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001048279.